Spreadsheet: e33db9ca-6d79-4007-a21e-e403a0e26225
Sheet: PR_Total PR Cash Outflow_3A

On-going Progress Update and Disbursement Request
PROGRESS UPDATE PERIOD
Grant number:
Progress Update - Reporting Period: |  |  | Cycle: |  | Number:
Progress Update - Period Covered: |  |  | Beginning Date: |  | End Date:
Progress Update - Number:
Currency:
Section 3A: Total PR Cash Outflow
! For RCC grants the cumulative section of the table below should contain cumulative amount from the start of the RCC and not from the start of Phase 1 of the program.
 |  | Budget for Reporting Period | Actual Cash Outflow for Reporting Period | [NAME] | Reason for [NAME] |  | Cumulative Budget through period of Progress Update | Cumulative Actual Cash Outflow through period of Progress Update | [NAME] | Reason for [NAME]
1. Total PR cash outflow vs. budget
1a. PR's total expenditures |  | 1500000 | 1435000 |  | Not implemented: 50,000 Technical Assistance for lab assessment  Staff travel not realized in the amount of 15,000. |  | 2600000 | 2000000 |  | Contracts signed for procuring CD4 count equipment but not yet paid  - 300,000. Final installment per signed contract to be paid for transportation and storage of drugs in regional warehouses - 35,000. Savings: 100,000 from late recruitment of staff Delayed activities (in progress now): 265,000 (media campaign - 50,000, refurbishment of facilities for delivery of opioid substitution therapy - 150,000, trainings related to substitution therapy - $15,000) Advance payment: (100,000) for procurement of test systems brought forward from Q7 due to bulk order
1b. Disbursements to sub-recipients |  | 1000000 | 800000 |  | The PR has canceled a contract with one SR due to performance and accountability issues. Given the underperformance with regards to the set targets for prevention activities for commercial sex workers, the PR has decided to support  service delivery sites in additional cities and towns where the need for the work with this target group has been identified (initial findings of ongoing BSS activities).  The PR has signed contracts with new SRs after the end of the reporting period and plans to accelerate the work to achieve the targets.  The PR has developed with the new SRs an accelerated implementation plan, to be supported with the unused budgeted resources as of the end of Q5 (200,000) (see attached docs). |  | 3000000 | 2500000 |  | The PR has canceled a contract with one SR due to performance and accountability issues. Given the underperformance with regards to the set targets for prevention activities for commercial sex workers, the PR has decided to support  service delivery sites in additional cities and towns where the need for the work with this target group has been identified (initial findings of ongoing BSS activities).  The PR has signed contracts with new SRs after the end of the reporting period and plans to accelerate the work to achieve the targets.  The PR has developed with the new SRs an accelerated implementation plan, to be supported with the unused budgeted resources as of the end of Q5 (200,000) (see attached docs). Payments in the amount of 300,000 were not made to SRs by the end of the reporting period due to delays in submission of the SR reports or inconsistent reports. Payment in the amount of 280,000 was made to SR right after the end of the reporting period (for all SRs where the outstanding issues were successfully resolved).
 |  | Budget for Reporting Period* | Actual Cash Outflow for Reporting Period | [NAME] | Reason for [NAME] |  | Cumulative Budget through period of Progress Update | Cumulative Actual Cash Outflow through period of Progress Update | [NAME] | Reason for [NAME]
2. Total pharmaceutical & health product expenditures vs. budget
2a.  [NAME] and pharmaceutical products |  | 600000 |  |  | OI drugs cost less than initially budgeted (savings in the amount of 50,000). |  | 1000000 | 850000 |  | OI drugs cost less than initially budgeted (savings in the amount of 50,000). These savings are used to fund higher prices for some second-line ARVs.  There is a last installement for the annual order of ARV drugs in the amount 100,000 to be paid in the next quarter.
2b.  Health products and health equipment |  | 700000 |  |  | Advance payment: (100,000) for procurement of test systems brought forward from Q7 due to bulk order |  | 1500000 |  |  | Advance payment: (100,000) for procurement of test systems brought forward from Q7 due to bulk order.  The order for lab equipment was placed (total amount: 500,000) - payment will be made in installements in the next two quarters.